Goldberg Law PC represents investors around the world, and specializes in securities class action lawsuits and shareholder rights litigation.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between June 17, 2015 and August 10, 2017, inclusive (the "Class Period"), are encouraged to contact the firm before October 24, 2017, the lead plaintiff motion deadline. If you are a shareholder who suffered a loss during the Class Period, click here to participate. We also encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights free of charge. You can also reach us through the firm's website at http://www.goldberglawpc.com/, or by email at email@example.com. The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. The Complaint alleges that during the Class Period, Dr. Reddy's made false and/or misleading statements, and/or failed to disclose, that the Company lacked an effective corporate quality system; and thus its public statements were materially false and misleading at all relevant times. On August 10, 2017, Dr. Reddy's disclosed that the Regulatory of Germany (Regierung von Oberbayern) did not renew the good manufacturing practices compliance certificate of a formulations manufacturing unit of its German subsidiary Betapharm Arzneimittel, located in Hyderabad, India, following a recent inspection of the plant. Following this news, shares of Dr. Reddy's dropped in value materially, which caused investors harm.